Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:15 PM
Ignite Modification Date:
2025-12-24 @ 11:15 PM
NCT ID:
NCT06024356
Eligibility Criteria:
Inclusion Criteria:
* Patients with rectal adenocarcinoma must satisfied all the following conditions:
1. Stage II/III LARC (cT1-4aN0-2M0);
2. Tumor distal location≤10 cm from anal verge (MRI diagnosed);
* Patients regardless of gender with aged≥18 years
* ECOG score of 0 or 1
* Physical and viscera function of patients can withstand major abdominal surgery
Exclusion Criteria:
* Current or previous active malignancy other than rectal cancer；
* Patients underwent major surgery within 4 weeks prior to neoadjuvant therapy；
* Patients have any condition affects the absorption of capecitabine through gastrointestinal tract；
* Patients have severe uncontrolled recurrent infections, or other severe uncontrolled concomitant diseases;
* Patients with severe concomitant diseases with estimated survival≤5 years；
* Patients with present or previous moderate or severe liver and kidney damage；
* Patients preparing for or previously received organ or bone marrow transplant；
* Patients who have received immunosuppressive or systemic hormone therapy within 1 month prior to the start of neoadjuvant therapy；
* Patients with congenital or acquired immune deficiency (such as HIV infection)；
* Pregnant or lactating women.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06024356
Study Brief:
Protocol Section:
NCT06024356